As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Progressive Restless Legs Syndrome – pipeline landscape globally. Progressive Restless Legs Syndrome Pipeline Insight, 2023” report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:https://www.globalinsightservices.com/request-sample/GIS31210
Restless Legs Syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move one’s legs. The exact cause of RLS is unknown, but it is thought to be associated with a dysfunction in the brain’s dopamine system. This system is responsible for regulating movement and is also involved in the feeling of pleasure and reward. RLS is thought to be caused by a combination of genetic and environmental factors. Other conditions that contribute to RLS include low levels of iron (iron deficiency), uremia, hypothyroidism, depression, fibromyalgia and Parkinson’s disease.
Symptoms of RLS include leg (or arm) discomfort, urge to move legs, sleep disruption, bedtime behavior problems and daytime sleepiness.
Healthcare provider may conduct a physical and a neurological exam. Other tests like blood tests may be recommended.
Restless legs syndrome can be treated with non-drug treatments like regular exercise, good sleeping habits and iron supplementation prescription medications like dopamine agonists and anti-seizure medications.
RLS is a relatively common disorder, affecting up to 10% of the population. It is more common in women and people of European descent. RLS is often associated with other conditions, such as iron deficiency, pregnancy, and certain neurological disorders.
There is no cure for RLS, but treatments are available to help relieve the symptoms. These include dopaminergic medications, iron supplements, and lifestyle changes.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Restless legs syndrome, such as LY03009 and others. Key players involved in the development of therapies to treat restless legs syndrome are Eli Lilly and Co., Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb, and others. Three drugs are in Phase I and some other drugs in preclinical stage of development.
Report Highlights
Global Insight Service’s, Restless Legs Syndrome – Drug Pipeline Landscape, 2023 report provides an overview of the Restless Legs Syndrome pipeline drugs. This report covers detailed insights on Restless Legs Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Restless Legs Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Buy Now:https://www.globalinsightservices.com/checkout/single_user/GIS31210
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/